Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza Vaccine in children 6-35 months of age

Pediatric Infectious Disease Journal

Volumn 33, Issue 12, 2014, Pages e320-e329

  Knuf, Markus ^a   Leroux Roels, Geert ^b   Rümke, HanS C ^c   Abarca, Katia ^d   Rivera, Luis ^e   Lattanzi, Maria ^f   Pedotti, Paola ^f   Arora, Ashwani ^f   Kieninger Baum, Dorothee ^a   Della Cioppa, Giovanni ^f  

^a Zentrum für Kinder und Jugendmedizin Universitätsmedizin   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c University Vaccine Center Rotterdam Nijmegen   (Netherlands)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e Hospital Maternidad Ntra Sra de la Altagracia   (Dominican Republic)

^f Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

A H1N1; MF59; Pandemic influenza; Pediatric; Vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; MIFAMURTIDE; SIALIDASE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; NEUTRALIZING ANTIBODY; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADJUVANT THERAPY; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; BRONCHITIS; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DELTOID MUSCLE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; ETHNIC GROUP; FEMALE; FEVER; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEASONAL INFLUENZA; SEROCONVERSION; SHIVERING; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; VIROGENESIS; VOMITING; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; SERODIAGNOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NEUTRALIZATION TESTS; POLYSORBATES; SQUALENE; VACCINATION;

EID: 84926215593     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000462     Document Type: Article

References (38)

1. World Health Organization. World now at the start of 2009 influenza pandemic. Available at: http://www.who.int/mediacentre/news/statements/2009/h1n1-pandemic-phase6-20090611/en/index.html. Accessed August 27, 2014.
2. Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature. 2006;442:448-452.
3. Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine. 2006;24:1047-1062.
4. Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science. 2009;325:1705-1708.
5. Jain S, Kamimoto L, Bramley AM, et al.; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935-1944.
6. Glatman-Freedman A, Portelli I, Jacobs SK, et al. Attack rates assessment of the 2009 pandemic H1N1 influenza A in children and their contacts: a systematic review and meta-analysis. PLoS One. 2012;7:e50228.
7. Arguedas A, Soley C, Abdelnour A, et al.; Costa Rican H1N1 Vaccine Study Group. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin. 2011;7:58-66.
8. Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin. 2011;7:539-548.
9. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009;361:2424-2435.
10. Tsai TF, Crucitti A, Nacci P, et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis. 2011;43:702-706.
11. Gasparini R, Schioppa F, Lattanzi M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract. 2010;64:432-438.
12. Fukase H, Furuie H, Yasuda Y, et al. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Vaccine. 2012;30:5030-5037.
13. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6:699-710.
14. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines. 2003;2:197-203.
15. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J. 2009;28:563-571.
16. European Medicines Agency. European Public Assessment Report for Focetria. June 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000710/WC500023756.pdf. Accessed August 27, 2014.
17. Hatz C, von Sonnenburg F, Casula D, et al. A randomized clinical trial to identify the optimal antigen and MF59 ((R)) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine. 2012;30:3470-3477.
18. Keitel WA, Atmar RL. Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol. 2009;333:431-451.
19. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343-1351.
20. World Health Organization. Influenza vaccines. WHO position paper. Weekly Epidemiological Record. August 19, 2005, vol. 80, 33, 277-288.
21. World Health Organization. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development X-179A. Available at: http://www.who.int/csr/resources/publications/swineflu/candidates-X-179a/en/. Accessed August 27, 2014.
22. Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis. 2004;4:499-509.
23. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357:1937-1943.
24. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081-1085.
25. Bonhoeffer J, Bentsi-Enchill A, Chen RT, et al.; Brighton Collaboration Methods Working Group. Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine. 2009;27:2282-2288.
26. Committee for the Proprietary Medical Products. Note for guidance on harmonization of requirements for influenza vaccines. March 1997. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003945.pdf. Accessed August 27, 2014.
27. Yasuda Y, Komatsu R, Matsushita K, et al. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv Ther. 2010;27:444-457.
28. Garcia-Sicilia J, Gillard P, Carmona A, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine. 2011;29:4353-4361.
29. Roman F, Vaman T, Kafeja F, et al. AS03 (A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 2010;51:668-677.
30. Hoschler K, Andrews NJ, Faust SN, et al. Administration of AS03Badjuvanted A (H1N1) pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. Clin Infect Dis. 2014;58:181-187.
31. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ. 2010;340:c2649.
32. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009;106:7962-7967.
33. Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009;27:6291-6295.
34. Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and nonadjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28:4123-4129.
35. Khurana S, Chearwae W, Castellino F, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med. 2010;2:15ra5.
36. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3:85ra48.
37. Esposito S, Pugni L, Daleno C, et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics. 2011;127:e1161-e1168.
38. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365:1406-1416.